SCHEMBL5268848

SCHEMBL5268848

CNCCC(Oc1ccc(OC)cc1)c1ccccc1

nearest known ligand 0.82

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A4 P31645 14/20 0.82
SLC6A2 P23975 6/20 0.70
MEN1 O00255 5/20 0.70
KMT2A Q03164 5/20 0.70
LMNA P02545 4/20 0.70
CYP2D6 P10635 4/20 0.70
CYP2C19 P33261 3/20 0.70
CYP3A4 P08684 3/20 0.70
SLC6A3 Q01959 3/20 0.70
NPC1 O15118 2/20 0.70
MTOR P42345 2/20 0.70
RAB9A P51151 2/20 0.70
CYP1A2 P05177 2/20 0.70
TSHR P16473 2/20 0.70
HTR2C P28335 2/20 0.70
KDM4E B2RXH2 1/20 0.70
TP53 P04637 1/20 0.70
CYP2C9 P11712 1/20 0.70
ALOX15 P16050 1/20 0.70
NFKB1 P19838 1/20 0.70

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5011928 0.90 SLC6A4 (1.00) SLC6A4SLC6A2MEN1KMT2ALMNA
SCHEMBL8197696 0.90 SLC6A4 (1.00) SLC6A4SLC6A2MEN1KMT2ALMNA
Hydrochloric Acid SCHEMBL4941345 0.89 SLC6A4 (0.97) SLC6A4SLC6A2MEN1KMT2ALMNA
SCHEMBL5015289 0.88 SLC6A4 (0.82) SLC6A4SLC6A2MEN1KMT2ALMNA
SCHEMBL13107035 0.88 SLC6A4 (0.82) SLC6A4SLC6A2MEN1KMT2ALMNA
SCHEMBL7053900 0.87 SLC6A4 (0.75) SLC6A4SLC6A2MEN1KMT2ALMNA
SCHEMBL7051333 0.86 SLC6A4 (1.00) SLC6A4SLC6A2MEN1KMT2ALMNA
Hydrochloric Acid SCHEMBL4942454 0.86 SLC6A4 (0.79) SLC6A4SLC6A2MEN1KMT2ALMNA
SCHEMBL7055186 0.86 SLC6A4 (1.00) SLC6A4SLC6A2MEN1KMT2ALMNA
Hydrochloric Acid SCHEMBL17685574 0.86 SLC6A4 (0.79) SLC6A4SLC6A2MEN1KMT2ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070270483-A1 PROCESS FOR THE PREPARATION OF ARYLOXYPROPYLAMINES DIPHARMA FRANCIS S.R.L. (IT) 2007-11-22 US claimed
EP-1857435-A2 A process for the preparation of aryloxypropylamines Dipharma Francis S.r.l. (IT) 2007-11-21 EP claimed
EP-0831799-B1 COMPOUNDS ACTIVE AT A NOVEL SITE ON RECEPTOR-OPERATED CALCIUM CHANNELS USEFUL FOR TREATMENT OF NEUROLOGICAL DISORDERS NPS PHARMA INC (US) 2003-05-02 EP claimed
US-20070270483-A1 PROCESS FOR THE PREPARATION OF ARYLOXYPROPYLAMINES DIPHARMA FRANCIS S.R.L. (IT) 2007-11-22 US disclosed
EP-1857435-A2 A process for the preparation of aryloxypropylamines Dipharma Francis S.r.l. (IT) 2007-11-21 EP disclosed
EP-0336753-B1 IMPROVEMENTS IN OR RELATING TO PROPANAMINE DERIVATIVES ELI LILLY AND COMPANY (US) 1992-07-08 EP disclosed
EP-0336753-A1 Improvements in or relating to propanamine derivatives ELI LILLY AND COMPANY (US) 1989-10-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070270483-A1 PROCESS FOR THE PREPARATION OF ARYLOXYPROPYLAMINES NAT1, C1S, PAH SLC6A4 310/4885SLC6A2 104/4885MEN1 114/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.